Study Description
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Eligibility Criteria
Inclusion Criteria:
* All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).
Exclusion Criteria:
* Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)
Novartis Investigative Site
Recruiting
Toyoake,Aichi-ken,4701192,Japan
Novartis Investigative Site
Recruiting
Hiroshima,734 8530,Japan
Novartis Investigative Site
Recruiting
Tokushima,Tokushima,7708503,Japan
Novartis Investigative Site
Recruiting
Suita,Osaka,565-0871,Japan
Novartis Investigative Site
Recruiting
Chiba,Chiba,2608677,Japan
Novartis Investigative Site
Recruiting
Hirosaki,Aomori,036 8563,Japan
Novartis Investigative Site
Recruiting
Nakano City,Tokyo,164-8607,Japan
Novartis Investigative Site
Recruiting
Nagasaki,Nagasaki,852-8501,Japan
Novartis Investigative Site
Recruiting
Kitakyushu,Fukuoka,8028555,Japan
Novartis Investigative Site
Recruiting
Nagoya,Aichi-ken,466-8650,Japan
Novartis Investigative Site
Recruiting
Shimotsuga Gun,Tochigi,321-0293,Japan
Novartis Investigative Site
Recruiting
Shimajiri-Gun,Okinawa,901-1303,Japan
Novartis Investigative Site
Recruiting
Shinjuku Ku,Tokyo,1628666,Japan
Novartis Investigative Site
Recruiting
Sapporo,Hokkaido,060-8604,Japan
Novartis Investigative Site
Recruiting
Fuchū,Tokyo,1838561,Japan
Novartis Investigative Site
Recruiting
Ohtsu,Shiga,5202192,Japan
Novartis Investigative Site
Recruiting
Kusatsu,Shiga,525-8585,Japan
Novartis Investigative Site
Recruiting
Sapporo,Hokkaido,0040041,Japan
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.